Crovalimab Clinical Trials (2026): 10 Studies for Paroxysmal Nocturnal Hemoglobinuria & Atypical Hemolytic Uremic Syndrome
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Crovalimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Paroxysmal Nocturnal Hemoglobinuria & Atypical Hemolytic Uremic Syndrome) and 759 total planned enrollment. 6 Phase 3 Crovalimab trials and 2 Phase 2 are listed. Most recent activity: NCT07172022 (Dec 2030).
Crovalimab clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | withdrawn | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P1/P2 | 1 | 1 | ||
| P2 | 1 | 1 | 2 | |
| P3 | 5 | 1 | 6 |
Crovalimab clinical trials by indication
Paroxysmal Nocturnal Hemoglobinuria (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04434092 | COMMODORE 2 | P3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors |
| NCT04432584 | COMMODORE 1 | P3 | active not recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors |
| NCT04654468 | COMMODORE 3 | P3 | active not recruiting | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition |
Sickle Cell Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05075824 | CROSSWALK-c | P2 | completed | A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) |
| NCT04912869 | CROSSWALK-a | P1 | completed | A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD). |
Atypical Hemolytic Uremic Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04861259 | COMMUTE-a | P3 | active not recruiting | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) |
| NCT04958265 | COMMUTE-p | P3 | active not recruiting | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) |
Antiphospholipid Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07172022 | APS | P2 | withdrawn | A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) |
Guillain-Barré Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05494619 | GBS | P3 | withdrawn | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) |
Paroxysmal Hemoglobinuria, Nocturnal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03157635 | COMPOSER | P1/P2 | active not recruiting | Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria |
Crovalimab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| COMMUTE-a | NCT04861259 | P3 | active not recruiting | Atypical Hemolytic Uremic Syndrome | 83 | — |
| COMMUTE-p | NCT04958265 | P3 | active not recruiting | Atypical Hemolytic Uremic Syndrome | 41 | — |
| COMMODORE 2 | NCT04434092 | P3 | active not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 210 | — |
| COMMODORE 1 | NCT04432584 | P3 | active not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 190 | — |
| COMMODORE 3 | NCT04654468 | P3 | active not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 51 | — |
| GBS | NCT05494619 | P3 | withdrawn | Guillain-Barré Syndrome | 0 | — |
| APS | NCT07172022 | P2 | withdrawn | Antiphospholipid Syndrome | 0 | — |
| CROSSWALK-c | NCT05075824 | P2 | completed | Sickle Cell Disease | 95 | — |
Terminated and withdrawn Crovalimab trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT07172022withdrawnA Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
- NCT05494619withdrawnA Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
All Crovalimab trials (10)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07172022 | APS | A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) | P2 | withdrawn | 0 | Hoffmann-La Roche | Mar 2026 |
| NCT04861259 | COMMUTE-a | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | P3 | active not recruiting | 83 | Hoffmann-La Roche | Oct 2021 |
| NCT04958265 | COMMUTE-p | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | P3 | active not recruiting | 41 | Hoffmann-La Roche | Nov 2021 |
| NCT04434092 | COMMODORE 2 | A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors | P3 | active not recruiting | 210 | Hoffmann-La Roche | Oct 2020 |
| NCT04432584 | COMMODORE 1 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | P3 | active not recruiting | 190 | Hoffmann-La Roche | Sep 2020 |
| NCT04654468 | COMMODORE 3 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition | P3 | active not recruiting | 51 | Hoffmann-La Roche | Mar 2021 |
| NCT05494619 | GBS | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) | P3 | withdrawn | 0 | Hoffmann-La Roche | Nov 2022 |
| NCT03157635 | COMPOSER | Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria | P1/P2 | active not recruiting | 59 | Hoffmann-La Roche | Nov 2016 |
| NCT05075824 | CROSSWALK-c | A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) | P2 | completed | 95 | Hoffmann-La Roche | Mar 2022 |
| NCT04912869 | CROSSWALK-a | A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD). | P1 | completed | 30 | Hoffmann-La Roche | Mar 2022 |
Crovalimab clinical trials: frequently asked questions
- How many Crovalimab clinical trials are there?
- 10 Crovalimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are marked completed.
- Are Crovalimab clinical trials recruiting in 2026?
- No active Crovalimab trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Crovalimab being studied for?
- Crovalimab is being studied for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Sickle Cell Disease, Antiphospholipid Syndrome, Guillain-Barré Syndrome and 1 more. The trials are grouped by indication on this page.
- What phase is Crovalimab in?
- Crovalimab clinical trials span 6 Phase 3, 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Crovalimab clinical trials?
- The lead sponsor across the most Crovalimab trials is Hoffmann-La Roche. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Crovalimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: